S1400, known as Lung-MAP, has registered 1,400 patients.
This marks a major milestone for SWOG's precision medicine trial. Launched in 2014, Lung-MAP is the National Cancer Institute's first precision medicine trial, and is testing new biomarker driven therapies as well as immunotherapy and immunotherapy combinations for patients with advanced squamous cell lung cancer. The trial, managed by SWOG, is a partnership that includes the NCI, Friends of Cancer Research, and the Foundation for the National Institutes of Health. Learn more at www.lung-map.org.